Document Detail


Re-Examining the Recommended Follow-Up Interval after an In-Range INR Value: Results from the Veterans AffaiRs Study to Improve Anticoagulation (VARIA).
MedLine Citation:
PMID:  21310837     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
ABSTRACT BACKGROUND: Patients receiving oral anticoagulation should be tested often enough to optimize control, but excessive testing increases burden and cost. We examined the relationship between the follow-up interval after an in-range (2.0-3.0) INR and anticoagulation control. METHODS: We studied 104,451 patients receiving anticoagulation from 100 anticoagulation clinics in the Veterans Health Administration (VA). Most patients (98,877) recorded at least one in-range INR followed by another INR within 56 days. For each such patient, we selected the last in-range INR and characterized the interval between this "index value" and the next INR. The independent variable was site mean follow-up interval after an in-range INR. The dependent variable was site mean risk-adjusted percent time in therapeutic range (TTR). RESULTS: Site mean interval varied from 25-38 days. As the mean site follow-up interval became longer, risk-adjusted TTR was worse (-0.51% per day, p = 0.004). This relationship persisted when the index value was the first consecutive in-range INR (-0.63%, p < 0.001), or the second (-0.58%, p < 0.001), but not the third or greater (-0.12%, p = 0.46). CONCLUSIONS: Sites varied widely regarding follow-up intervals after in-range INR (25-38 days). Shorter intervals were generally associated with better anticoagulation control, but after a third consecutive in-range value, this relationship was greatly attenuated and no longer statistically significant. Our results suggest that a maximum interval of 28 days after the first or second in-range value and consideration of a longer interval after the third or greater consecutive in-range value may be appropriate.
Authors:
Adam J Rose; Al Ozonoff; Dan R Berlowitz; Arlene S Ash; Joel I Reisman; Elaine M Hylek
Related Documents :
23129737 - Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovari...
23551657 - Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage:...
24431257 - Evaluation of effectiveness of kinesiology taping as an adjunct to rehabilitation follo...
24655407 - A prospective, randomized, controlled study of omega-3 fish oil fat emulsion-based pare...
10075297 - The absent role of prophylactic antibiotics in low-risk patients undergoing laparoscopi...
17199477 - Comparative study using 685-nm and 830-nm lasers in the tissue repair of tenotomized te...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-2-10
Journal Detail:
Title:  Chest     Volume:  -     ISSN:  1931-3543     ISO Abbreviation:  -     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-2-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0231335     Medline TA:  Chest     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
1Center for Health Quality, Outcomes, and Economic Research, Bedford VA Medical Center, Bedford, MA;
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Randomized trial of a behavioral intervention to prevent excessive gestational weight gain: the Fit ...
Next Document:  Effects of BMI on static lung volumes in patients with airway obstruction.